Editors' ChoiceMEDICINE

Papers of note in Science Translational Medicine 9 (404)

See allHide authors and affiliations

Sci. Signal.  29 Aug 2017:
Vol. 10, Issue 494, eaap7469
DOI: 10.1126/scisignal.aap7469

This week’s articles describe potential therapeutic strategies to reduce hydrocephaly in infants, to kill liver cancer cells, and to improve MeCP2-associated neurological disorders.

DRUG DEVELOPMENT

Repurposing diabetic drugs for hydrocephalus

Botfield et al. show that a small-molecule agonist of glucagon-like peptide-1 receptor (GLP-1R), currently used to treat diabetes and obesity, reduced the Na+ and K+ ATPase-dependent secretion of cerebrospinal fluid that causes hydrocephaly.

Killing cancer with ER stress

Zhang et al. discover that combining an oncolytic virus with an inhibitor of valosin-containing protein (VCP) triggered irresolvable, cytotoxic endoplasmic reticulum (ER) stress in hepatocellular carcinoma cells.

A HIP way to treat MeCP2 disorders

Lombardi et al. find that targeting HIPK2 (homeodomain-interacting protein kinase 2) or PP2A (protein phosphatase 2A) modulates the stability of methyl-CpG–binding protein 2 (MeCP2), which may be therapeutic in some neurological disorders.

Highlighted Articles

View Abstract

Navigate This Article